Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RARX

Ra Pharmaceuticals (RARX) Stock Price, News & Analysis

Ra Pharmaceuticals logo

About Ra Pharmaceuticals Stock (NASDAQ:RARX)

Advanced Chart

Key Stats

Today's Range
$47.99
$47.99
50-Day Range
$47.99
$48.00
52-Week Range
$19.64
$48.02
Volume
30,200 shs
Average Volume
1.16 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RARX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RARX Stock News Headlines

RA: Discount Continues To Leave Some Opportunity
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
RARX_old Historical Data
See More Headlines

RARX Stock Analysis - Frequently Asked Questions

Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its quarterly earnings results on Thursday, February, 27th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.16.

Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Verastem (VSTM), Amarin (AMRN), Bausch Health Cos (BHC) and Galmed Pharmaceuticals (GLMD).

Company Calendar

Last Earnings
2/27/2020
Today
7/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RARX
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$102.69 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3 million
Price / Cash Flow
N/A
Book Value
$5.56 per share
Price / Book
8.63

Miscellaneous

Free Float
N/A
Market Cap
$2.27 billion
Optionable
Optionable
Beta
1.05
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:RARX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners